Abstract:Abstract Introduction: Liver cancer is the second cause of cancer-related mortality worldwide. Currently, there are only two systemic agents able to increase survival in patients at advanced stages (i.e. sorafenib and regorafenib). Median survival of these patients is still poor, which highlights the need for new therapies. Our aim is to identify key regulatory gene networks with oncogenic properties amenable for therapeutic intervention through 1) integration of gene expression and DNA methylation data from human HCC samples followed by 2) functional validation in mice using shRNA screens. Methods: DNA methylation (Illumina HM450) and mRNA expression (Affymetrix human genome U219) data of 215 human HCC samples (Villanueva, Hepatology 2015) were analyzed to identify key gene regulatory networks. A causality test interrogated the impact of cis and trans regulation of promoter methylation on gene expression (Yoo, PLoS Genet 2015). A key regulator gene was defined when it regulated a substantial number of downstream genes (more than 2 standard deviations from the mean predicted trans-regulated downstream genes). Data analysis includes differential gene expression, topological overlap clustering (hierarchical, non-negative factorization [NMF]), and gene annotation. The tumorigenic potential of candidate tumor suppressors was experimentally validated through a positive selection shRNA (short-hairpin RNA) screen in mice (6 shRNAs/gene, 48 shRNAs/pool, 5 mice/library). Results: We identified 116 potential HCC key regulator genes, predicted to regulate expression of between 1,484 and 3,511 downstream genes for each one. Among the key regulators, 60 were classified as potential tumor maintenance genes and 56 as potential tumor suppressors genes based on differential expression with non-tumoral tissue (FDR<0.05). Hierarchical clustering of downstream genes showed significant overlap among multiple key regulators, suggesting their function in co-regulatory networks. Gene annotation showed a majority of key regulators associated (FDR<0.05) with focal adhesion and matrix reorganization. Three clusters of patients emerged upon NMF clustering of the key regulator’s gene expression, one of which showed (n=69/215, 32% of patients) significant overlap with the previously described CTNNB1 subclass of HCC (Chiang, Cancer Res 2008). In mice, 2/6 shRNA libraries showed significant accelerated tumor growth when compared to control [median time to 400 cc of tumor volume were 29 (library #2) and 30 (library #3) versus 39 days in control, P<0.05], suggesting enrichment of bona fide tumor suppressors. Planned sequencing analysis will confirm the identity of these candidates. Conclusions: We have identified 116 putative key regulators of hepatocarcinogenesis by integrative analysis of gene expression and DNA methylation. Functional validation indicates enrichment of bona fide tumor suppressors. Citation Format: Amanda J. Craig, Seungyeul Yoo, Verónica Miguela, Delia D'Avola, Pedro Molina-Sánchez, Josep Llovet, Amaia Lujambio, Jun Zhu, Augusto Villanueva. Integrative molecular analysis of gene expression and methylation reveals 116 putative key regulator genes of human hepatocarcinogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4393. doi:10.1158/1538-7445.AM2017-4393

Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma

A Novel Heterozygous Mutation in the HMBS Gene in a Patient with Acute Intermittent Porphyria and Posterior Reversible Encephalopathy Syndrome

HBV Rewires Liver Cancer Signaling by Altering PP2A Complexes

Establishment and Validation of a Novel Risk Score for Hepatocellular Carcinoma Based on Bile Acid and Bile Salt Metabolism-Related Genes.

Caractérisation Moléculaire Des Carcinomes Hépatocellulaires Liés Au Virus De L'hépatite B

Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Novel hydroxymethylbilane synthase gene mutation identified and confirmed in a woman with acute intermittent porphyria: A case report

Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data

Abstract 1255: Identification of Mutational Landscape Predicting Efficacy of Immune Checkpoint Blockades and Recurrent Mutations Related to High Tumor Mutational Burden in Hepatocellular Carcinoma by Next Generation Sequencing

From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria

Nontargeted urine metabolomic analysis of acute intermittent porphyria reveals novel interactions between bile acids and heme metabolism: New promising biomarkers for the long‐term management of patients

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

HP1s modulate the S-Adenosyl Methionine synthesis pathway in liver cancer cells

Characterization of heterogeneous metabolism in hepatocellular carcinoma identifies new therapeutic target and treatment strategy

Mechanistic basis for targeting homologous recombination defective liver cancer via synthetic lethality

Abstract 4393: Integrative Molecular Analysis of Gene Expression and Methylation Reveals 116 Putative Key Regulator Genes of Human Hepatocarcinogenesis

Heterogeneous phenotypes of Pten-null hepatocellular carcinoma in hepatitis B virus transgenic mice parallels liver lobule zonal gene expression patterns

An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC)

Identification of Two Distinct Immune Subtypes in Hepatitis B Virus (HBV)-Associated Hepatocellular Carcinoma (HCC)

Abstract A25: Array-based Comparative Genomic Hybridization of Hepatocellular Carcinoma Reveals a Unique Genomic Aberration Pattern in Tumors with Poor Prognosis